[Translation] A randomized, double-blind, double-dummy, multicenter phase III clinical study on the efficacy and safety of candesartan cilexetil amlodipine tablets (8mg/5mg) in patients with primary mild to moderate hypertension whose blood pressure cannot be effectively controlled by candesartan cilexetil tablets (8mg) or amlodipine besylate tablets (5mg) alone for 4 weeks.

验证复方制剂相对于单方制剂的优效性。评价复方坎地沙坦酯氨氯地平片（8mg/5mg）用于坎地沙坦酯片（8mg）或苯磺酸氨氯地平片（5mg）单药治疗4周血压不能有效控制的原发性轻、中度高血压的有效性和安全性。

[Translation]

To verify the superiority of the compound preparation over the single preparation. To evaluate the efficacy and safety of compound candesartan cilexetil amlodipine tablets (8mg/5mg) in the treatment of primary mild and moderate hypertension whose blood pressure cannot be effectively controlled by candesartan cilexetil tablets (8mg) or amlodipine besylate tablets (5mg) for 4 weeks.

Start Date28 Aug 2024

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

CTR20232353 / CompletedNot Applicable

单中心、随机、开放、两周期、双交叉设计评价中国健康受试者单次空腹及餐后口服坎地沙坦酯氨氯地平片的人体生物等效性试验。

[Translation] A single-center, randomized, open-label, two-period, double-crossover design was used to evaluate the bioequivalence of candesartan cilexetil and amlodipine tablets in Chinese healthy subjects after single fasting and postprandial oral administration.

主要目的：以日本武田テバ薬品株式会社生产的坎地沙坦酯氨氯地平片（商品名：UNISIA；规格：坎地沙坦酯8mg与苯磺酸氨氯地平（按氨氯地平计）5mg）为参比制剂，以江西施美药业股份有限公司研发的坎地沙坦酯氨氯地平片（规格：坎地沙坦酯8mg与苯磺酸氨氯地平（按氨氯地平计）5mg）为受试制剂，通过单中心、随机、开放、两周期、双交叉设计的生物等效性试验来评价两种制剂在空腹及餐后条件下的生物等效性。次要目的：评估受试制剂坎地沙坦酯氨氯地平片和参比制剂UNISIA在中国健康成年受试者中的安全性。

[Translation]

Primary objective: Using candesartan cilexetil-amlodipine tablets (trade name: UNISIA; specification: candesartan cilexetil 8 mg and amlodipine besylate (calculated as amlodipine) 5 mg) produced by Takeda Teba Pharmaceutical Co., Ltd. of Japan as the reference preparation, and candesartan cilexetil-amlodipine tablets (specification: candesartan cilexetil 8 mg and amlodipine besylate (calculated as amlodipine) 5 mg) developed by Jiangxi Shimei Pharmaceutical Co., Ltd. as the test preparation, a single-center, randomized, open, two-period, double-crossover bioequivalence study was conducted to evaluate the bioequivalence of the two preparations under fasting and postprandial conditions. Secondary objective: To evaluate the safety of the test preparation candesartan cilexetil-amlodipine tablets and the reference preparation UNISIA in healthy adult subjects in China.

Start Date28 Aug 2023

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

NCT04611932 / Unknown statusPhase 1

A Randomized, Open-label, Single Dose, 3-period Partial Replicated Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers Under Fasting Conditions

This study is a randomized, open-label, single dose, 3-period partial replicated crossover study to evaluate the pharmacokinetic profiles and safety of CKD-333 low dose in healthy volunteers under fasting conditions.

Start Date11 Nov 2020

Sponsor / Collaborator

Chong Kun Dang Pharmaceutical Corp.

100 Clinical Results associated with Amlodipine Besylate/Candesartan Cilexetil

100 Translational Medicine associated with Amlodipine Besylate/Candesartan Cilexetil

100 Patents (Medical) associated with Amlodipine Besylate/Candesartan Cilexetil

100 Deals associated with Amlodipine Besylate/Candesartan Cilexetil

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C09DB07	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	KR	Chong Kun Dang Pharmaceutical Corp.	26 Jul 2016
Hypertension	JP	Takeda Pharmaceutical Co., Ltd.	06 Apr 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 2	-	Chong Kun Dang Pharmaceutical Corp.	01 Nov 2020
Dyslipidemias	Phase 2	KR	Chong Kun Dang Pharmaceutical Corp.	04 Apr 2018
Hyperlipidemias	Phase 2	KR	Chong Kun Dang Pharmaceutical Corp.	01 Dec 2016
Essential Hypertension	Phase 1	CN	Hainan Selection Pharmaceutical Co. Ltd.	27 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis